Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2138 in Resectable Pancreatic Ductal Adenocarcinoma
NCT07024615Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASP2138 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Astellas Pharma. Primary endpoints: Adverse Events at 11.5 months, Serious Adverse Events at 11.5 months and 6 more. Started Oct 2025; status: recruiting.
02
Drugs
ASP2138
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07024615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024615.